Navigation Links
Vista Partners Updates Coverage on Pro-Pharmaceuticals, Inc.; Maintains Target Price of $2.10
Date:12/23/2010

SAN FRANCISCO, Dec. 23, 2010 /PRNewswire/ -- Vista Partners announced today that it has updated coverage on Pro-Pharmaceuticals, Inc. (OTC Bulletin Board: PRWP) ("the Company") and maintains its twelve month target price to $2.10. Ross Silver, Principal Analyst at Vista Partners, stated, "DAVANAT®, the Company's lead product candidate, could potentially enhance the efficacy of already approved oncology drugs, such as Avastin®, while also reducing the side effect profile of these drugs. By doing so, patients potentially will live longer and live better and the cost of treatment could be reduced significantly." Mr. Silver goes on to state, "The Company has stated that development of its GR series of compounds, novel carbohydrate compounds intended to treat liver fibrosis, will commence in January 2011. The Company recently entered into a research agreement with the premier liver disease expert in the U.S., Dr. Scott Freidman, at Mt. Sinai Hospital in New York.  Liver disease is considerable and according to the American Liver Foundation, more than 25 million Americans are or have been afflicted with liver and biliary diseases."

To download a FREE copy of the Pro-Pharmaceuticals, Inc. research report, please visit www.vistapglobal.com and click the "download research" icon to gain access to the report.

About Vista Partners:

Vista Partners LLC was founded in 2005 and has offices in California and one in Oregon. We are a Registered Investment Advisor in the States of California and Oregon. Our professional staff has backgrounds in finance, corporate communications and investment banking. Vista Partners has built a name for itself in the small cap space due to its selection of profitable investment ideas.

Disclaimer & Disclosure:

For a full list of disclaimers and disclosures, please visit our website www.vistapglobal.com or click here.

Contact:

Ross Silver, 877.215.4813 or info@vistapglobal.com




'/>"/>
SOURCE Vista Partners
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. New FORTEO® and EVISTA® Data to be Presented at Premiere Scientific Meeting for Bone and Mineral Research
2. Vista Partners Updates Coverage on Raptor Pharmaceutical Corp.
3. U.S. Court of Appeals Upholds Validity of Lillys Evista Patents Through March of 2014
4. Chula Vistas Dr. Peter Rullan Adds Alma Lasers Pixel CO2 Laser System to Offer Fractional CO2 Laser Treatments to Patients
5. Biovista Announces the Appointment of Clifford H. Farrah to its Advisory Board
6. New High-Resolution Computer Tomography Data Demonstrates EVISTA(R)s Effect on Bone Quality in Osteoporotic Patients
7. Watson Confirms EVISTA(R) Patent Challenge
8. Biovista Inc. and FDA to Collaborate on a Medication Safety Initiative
9. Biovista Inc. Named Top Innovator in Life Sciences
10. Phase III Trial Showed Investigational Compound Arzoxifene Was Superior to Evista(R) (raloxifene HCl) in Increasing BMD in Postmenopausal Women with Osteoporosis
11. Synvista Therapeutics Announces Termination of Clinical Trials of Alagebrium and SYI-2074 and Provides Business Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... 2017  Sensus Healthcare, Inc. (NASDAQ: ... the treatment of non-melanoma skin cancers and other ... therapy, today announced that it will report its ... on Thursday, February 2, 2017 after the market close. ... call with the investment community on Thursday, February 2, ...
(Date:1/19/2017)... 19, 2017   Science Exchange , the leading ... that the first five replication studies from the ... published in eLife today. Despite intense scrutiny around ... practical evaluation of reproducibility rates that may identify ... other assessments of reproducibility, the results of this ...
(Date:1/19/2017)... 2017 While various reports ... reducing the FDA,s regulatory strictness as a way ... drug industry, many of the leading biotech and ... and development of advanced drug treatments and therapies.  ... developments include:  Moleculin Biotech, Inc., (NASDAQ: ...
Breaking Medicine Technology:
(Date:1/19/2017)... ... January 19, 2017 , ... Dr. Andrew Lian-Jie ... and fellowship trained Mohs and cosmetic surgeon. After extensive dermatology research training at ... his internship in internal medicine at the Emory University and dermatology training at ...
(Date:1/19/2017)... NY (PRWEB) , ... January 19, 2017 , ... ... of Clinical Conductor CTMS, which provides a modern CTMS workflow designed to seamlessly ... management information has been condensed to a single page, maximizing usability and improving ...
(Date:1/19/2017)... ... January 19, 2017 , ... Students interested in video can get a ... The winner will earn a $1,000 scholarship and have his or her video posted ... the deadline is May 31, with the winner announced on June 9. , The ...
(Date:1/19/2017)... ... 19, 2017 , ... Workrite Ergonomics announced this week the ... privacy panel system was designed to deliver the ideal blend of acoustic and ... provide the visual privacy required to maintain concentration levels and increase productivity. The ...
(Date:1/19/2017)... ... January 19, 2017 , ... Allegheny Health Network (AHN) ... who seek access to the Network’s programs and services in the greater Pittsburgh region. ... care appointments will be offered one for that same afternoon. , AHN ...
Breaking Medicine News(10 mins):